Case study: Improving wellbeing and persistence through digital support for CLL patients
Background
The Challenge
-
Chronic lymphocytic leukemia (CLL) requires ongoing emotional and physical resilience, as patients often face uncertainty, fatigue, and the psychological burden of a long-term diagnosis.
-
The introduction of a new twice-daily oral treatment regimen added complexity to patients’ routines, requiring strict adherence on top of other self-management behaviors.
-
Patients need support not only to understand and accept their condition, but also to build confidence in managing symptoms, side effects, and lifestyle adjustments over time.
-
The MyCLL program was designed to improve the overall patient experience, helping individuals persist with their treatment plan while enhancing their ability to self-manage and maintain quality of life.
Our Behavior Change Approach
-
Using the COM-B model we identified key behavioral drivers related to treatment adherence in CLL, and tailored the experience based on assessing each patient's drivers, needs and preferences.
-
We integrated the Brief Illness Perceptions Questionnaire (BIPQ) and a validated Quality of Life question to uncover patients’ beliefs, emotional responses, and perceived control over their condition.
-
The multichannel program provided digital self-management content addressing the needs and behavioral drivers, ensuring that each patient received relevant, meaningful support.
The Solution
The program experience over a 12 month journey included:
-
A personalized online portal providing a guided journey of emotional, behavioral and motivational support with a series of interactive e-Learning modules, articles, patient videos and stories as well as goal setting functionality
-
Nurse videos providing expert advice throughout the patient journey
-
Treatment reminders and behavior change SMS messages helping patients to optimise treatment adherence
-
An HCP feedback loop to ensure healthcare teams were informed of their patient’s progress
The Impact
Positive improvements were reported by participants:
-
32% improvement in perceived emotional wellbeing of patients
-
Improved day-to-day self-management such as symptom control by 31%
-
Reduced overall illness concerns by 32%
-
Quality of life rating increased by 16% over baseline.
-
Program retention rate was 94.3%.
-
Treatment persistence at 12 months was 94% for PSP patients compared to real-world data showing 81% with standard care.
